# Long-term outcomes for heart attack patients treated with a naturally-dissolving blood vessel support

Submission date	<b>Recruitment status</b> No longer recruiting	Prospectively registered		
04/06/2019		[_] Protocol		
Registration date	Overall study status	[] Statistical analysis plan		
07/06/2019	Completed	[X] Results		
Last Edited 20/01/2022	<b>Condition category</b> Circulatory System	[] Individual participant data		

### Plain English summary of protocol

Background and study aims

A bioresorbable scaffold (BRS) can hypothetically decrease the risk of an adverse cardiac event in the long-term perspective. The BRS is a device which is inserted into a blood vessel in order to expand the vessel to prevent or alleviate a blockage, manufactured from a material that may dissolve or be absorbed in the body. The of the study is to assess the long-term outcomes of using a BRS for the urgent treatment of coronary artery block.

Who can participate?

Patients undergoing surgery for STEMI type heart attack.

What does the study involve?

Patients undergoing urgent surgery for a STEMI type heart attack will be treated using the BRS and followed up over 5-years during their regular appointments.

What are the possible benefits and risks of participating? An improved long-term outcome with normal vessel anatomy (no vessel metallic cage as the device is resorbed over time). Higher risk of scaffold late thrombosis.

Where is the study run from?

1. University Hospital Kralovske Vinohrady third medical faculty, Charles University, Czechia

2. Military hospital Prague, Czechia

When is the study starting and how long is it expected to run for? December 2012 to December 2020

Who is funding the study? Univerzita Karlova v Praze (Charles University, Prague), Czechia Who is the main contact? Dr Petr Tousek, petr.tousek@fnkv.cz

## **Contact information**

**Type(s)** Scientific

**Contact name** Dr Petr Tousek

ORCID ID http://orcid.org/0000-0002-2598-3635

### **Contact details**

University Hospital Vinohrady Srobarova 50 Prague Czech Republic 10034 0042 067162701 petr.tousek@fnkv.cz

## Additional identifiers

**EudraCT/CTIS number** Nil known

**IRAS number** 

**ClinicalTrials.gov number** Nil known

**Secondary identifying numbers** Nil known

## Study information

**Scientific Title** Bioresorbable scaffold implantation in STEMI patients

Acronym PRAGUE-19

### Study objectives

Good longterm clinical outcome after bioresorbable scaffold (BRS) implantation, complete scaffold resorbtion at 5 year with stable lumen patency

### Ethics approval required

Old ethics approval format

**Ethics approval(s)** 1. Approved 09/01/2013, Local and multicenter ethical committee of the University Hospital Kralovske Vinohrady (Srobatrova 50, Prague 10, eticka.komise@fnkv.cz, +420267162272), ref: EK-VP/02/2013 2. Amendment approved 03/10/2018, ref: EK-VP/02/4/2013

**Study design** Prospective two-centre open-label registry study

**Primary study design** Observational

Secondary study design Longitudinal study

**Study setting(s)** Hospital

### Study type(s)

Treatment

### Participant information sheet

No participant information sheet available

### Health condition(s) or problem(s) studied

Acute myocardial infarction with ST segment elevation

### Interventions

Use of bioresorbable scaffold (AbsorbTM BRS) during primary coronary intervention. Patients enrolled in this study were treated during primary percutaneous coronary intervention (PCI) with the bioresorbable scaffold implantation (in some of the patients, optical coherence tomography (OCT) was performed just after BRS was implanted - if clinically possible). Patients are followed by clinical and phone controls during 5 years. First 25 eligible patients that agreed with the contol invasive imaging underwent 5 year coronary angiography and OCT.

### Intervention Type

Device

Phase IV

### Primary outcome measure

At 5 years:

- 1. Death using patient records
- 2. MI using patient records
- 3. Target vessel revascularization as recorded in records by a specialist

### Secondary outcome measures

Vessel invasive assessment using QCA and optical coherence tomography at baseline and 5 years.

Overall study start date 01/12/2012

Completion date

15/12/2020

## Eligibility

### Key inclusion criteria

STEMI patients
 Sign informed consent

Participant type(s)

Patient

**Age group** Adult

**Sex** Both

**Target number of participants** 130

**Total final enrolment** 117

Key exclusion criteria
1. Severe calcification
2. Do not meet specified vessel size
3. Length of the lesion more than 28mm
4. Indication for anticoagulation, cardiogenic shock

Date of first enrolment 15/12/2012

Date of final enrolment 15/12/2015

## Locations

**Countries of recruitment** Czech Republic **Study participating centre University Hospital Kralovske Vinohrady third medical faculty, Charles university** Srobarova 50 Prague Czech Republic 10034

#### **Study participating centre Military hospital Prague** U Vojenské nemocnice 1200 Prague Czech Republic 16902

### Sponsor information

**Organisation** Charles University, University Research programme UNCE 02 and PROGRES Q38

### Sponsor details

Ruska 87 Prague Czech Republic 10000 267162701 petr.tousek@f3.cuni.cz

**Sponsor type** University/education

Website www.cuni.cz

ROR https://ror.org/024d6js02

## Funder(s)

**Funder type** University/education

**Funder Name** 

Univerzita Karlova v Praze

Alternative Name(s) Charles University, Charles University in Prague, Univerzita Karlova, Karls-Universität zu Prag, UK

**Funding Body Type** Government organisation

**Funding Body Subtype** Universities (academic only)

**Location** Czech Republic

### **Results and Publications**

### Publication and dissemination plan

Pilot study published in 2014, 2-year interim analysis published in 2016, imaging analysis planned to published in 2019, final results in 2020.

### Intention to publish date

31/12/2020

### Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are not expected to be made available due to ethical restrictions on data sharing.

### IPD sharing plan summary

Not expected to be made available

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Other publications	interim analysis	17/05/2016	05/06/2019	Yes	No
Other publications	pilot study	01/03/2014	05/06/2019	Yes	No
<u>Results article</u>		30/01/2020	03/02/2020	Yes	No